

Status	(Multiple Items)
--------	------------------

Drug Name	Tumour Group	Regimen Name on NCCP website	Regimen Number
5-Fluorouracil	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
		5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day	421
		Aflibercept-14 days	238
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen	460
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429
		FLOT Therapy-14 day	344
		FLOX Therapy	486
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOX-4 Therapy-14 day	210
		FOLFOXIRI Therapy	555
		Modified FOLFIRINOX Therapy	515
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509
		Modified FOLFOX-6 Therapy-14 day	209
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594
		Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen	427
		5-Fluorouracil and Folinic Acid Therapy-14 day	660
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Cetuximab and FOLFOX-4 Therapy	692
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
		Cetuximab and FOLFOX-6 (modified) Therapy	733
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
		Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816

5-Fluorouracil	Gastrointestinal	Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832		
		Pembrolizumab and FOLFOX-6 Modified Therapy	839		
		Nivolumab and FOLFOX-6 Modified Therapy	844		
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446		
		Bevacizumab 5mg/kg, 5-Fluorouracil and Folinic Acid Therapy-14 dayi	791		
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450		
	Head & Neck	CARBOplatini (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle	552		
		Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418		
		Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle	417		
		CISplatin and 5-Fluorouracil Therapy-28 day	314		
		DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324		
		DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323		
		CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy	589		
		CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy	591		
		Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705		
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706		
		DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315		
		Abemaciclib	Breast	Abemaciclib Therapy	619
		Abiraterone	Genitourinary	Abiraterone 1000mg and Prednisolone 5mg Therapy	577
Abiraterone and Prednisolone Therapy	103				
Acalabrutinib	Lymphoma and Other Lymphoproliferative Disorders	Acalabrutinib (Tablets) Monotherapy	840		
Afatinib	Lung	Afatinib Monotherapy	221		
Aflibercept	Gastrointestinal	Aflibercept-14 days	238		
Alectinib	Lung	Alectinib Monotherapy	401		
Alemtuzumab	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611		
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625		
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638		
Anastrozole	Breast	Anastrozole Monotherapy	254		
Apalutamide	Genitourinary	Apalutamide therapy	574		
Arsenic trioxide	Leukaemia and Myeloid Neoplasma	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357		
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356		
Asciminib	Leukaemia and Myeloid Neoplasma	Asciminib Monotherapy	847		
Atezolizumab	Breast	Atezolizumab and nab-PACLitaxel Therapy	688		
	Gastrointestinal	Atezolizumab and Bevacizumab Therapy	831		
	Genitourinary	Atezolizumab 1680mg Monotherapy – 28 Day	593		
		Atezolizumab Monotherapy-14 day	592		
		Atezolizumab Monotherapy – 21 Day	544		

Atezolizumab	Lung	Atezolizumab 1680mg Monotherapy – 28 Day	593
		Atezolizumab Monotherapy-14 day	592
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
		Atezolizumab Monotherapy – 21 Day	544
	Lung	Atezolizumab 1680mg Monotherapy – 28 Day	593
		Atezolizumab Monotherapy – 21 Day	544
Atezolizumab SC	Gastrointestinal	Atezolizumab and Bevacizumab Therapy	831
	Genitourinary	Atezolizumab Monotherapy – 21 Day	544
	Lung	Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
		Atezolizumab Monotherapy – 21 Day	544
	Lung	Atezolizumab Monotherapy – 21 Day	544
Avelumab	Skin/Melanoma	Avelumab Monotherapy	535
Axicabtagene ciloleucel	CAR-T	Axicabtagene ciloleucel (Yescarta®) (CAR-T) DLBCL and PMBCL	717
Axitinib	Genitourinary	Axitinib Monotherapy	104
		Pembrolizumab 200mg and Axitinib Therapy	583
Azacitidine	Leukaemia and Myelodysplastic Syndromes	Azacitidine 100mg/m2 5-day Therapy	288
		Azacitidine 75mg/m2 5-2-2 Therapy	287
Azacitidine	Leukaemia and Myelodysplastic Syndromes	azaCITIDine (Oral) Monotherapy	818
		Venetoclax and azaCITIDine Therapy	852
Bendamustine	Lymphoma and Other Lymphoproliferative Disorders	Brentuximab vedotin and Bendamustine Therapy	529
		Polatuzumab Vedotin, Bendamustine and ritUXimab Therapy	685
	Lymphoma and Other Lymphoproliferative Disorders	Bendamustine Monotherapy	527
		Obinutuzumab and Bendamustine Therapy-28 day cycle	424
		ritUXimab and Bendamustine Therapy	345
Bevacizumab	Breast	Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738
	Gastrointestinal	Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Bevacizumab 7.5mg/kg-21days	214
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	
		Therapy- 21 day	623
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	623
		Atezolizumab and Bevacizumab Therapy	831
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
		Bevacizumab 5mg/kg, 5-Fluorouracil and Folinic Acid Therapy-14 day	791

Bevacizumab	Genitourinary	Bevacizumab 10mg/kg-14days	212	
	Gynaecology	Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766	
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy	769	
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	799	
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811	
		Olaparib (Tablet) and Bevacizumab Therapy	746	
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy	772	
		Lung	Bevacizumab 15mg/kg - 21 days	215
			Bevacizumab 7.5mg/kg-21days	214
		Neuro-oncology	Lomustine and Bevacizumab 5mg/kg Therapy	742
	Lomustine and Bevacizumab 7.5mg/kg Therapy		804	
	Bevacizumab 5mg/kg Monotherapy – 14 Day		813	
Bicalutamide	Genitourinary	Bicalutamide Therapy	482	
binimetinib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563	
Bleomycin	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		Lymphoma and Other Lymphoproliferative Disorders	ABVD Therapy	290
		Escalated Dose BEACOPP 21 day Therapy	354	
Bleomycin	Lymphoma and Ot	Escalated Dose BEACOPDAC 21 Day Therapy	837	
Blinatumomab	Paediatric Oncology	Blinatumomab Paediatric Therapy	P00567	
		Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy	P00707	
	Leukaemia and Myeloid Neoplasma	Blinatumomab Therapy	538	
		Blinatumomab Therapy (ALL with MRD>0.1%)	590	
Bortezomib	Plasma Cell Disorders	Bortezomib , Melphalan and Prednisolone	275	
		Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274	
		Bortezomib and Dexamethasone Therapy	270	
		Bortezomib Maintenance Therapy- 14 day	435	
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416	
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299	

Bortezomib	Plasma Cell Disorders	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy	273
		Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756
		Bortezomib, Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781
		AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28-Day Therapy	652
		Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy	779
		bortezomib	Plasma Cell Disorders
Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	609		
Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy	695		
Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496		
Bosutinib	Leukaemia and Myeloid Neoplasma	Bosutinib Monotherapy	224
Brentuximab vedotin	Lymphoma and Other Lymphoproliferative Disorders	Brentuximab vedotin and Bendamustine Therapy	529
		Brentuximab vedotin Monotherapy	234
		Brentuximab vedotin and ICE Therapy	528
		Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisolONE (CHP) Therapy	801
		Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530
Brigatinib	Lung	Brigatinib Therapy	562
Busulfan	Transplant	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor	662
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663
Cabazitaxel	Genitourinary	Cabazitaxel and Prednisolone	101
Cabozantinib	Genitourinary	Cabozantinib Therapy	518

Capecitabine	Breast	Capecitabine Monotherapy	216		
		Lapatinib and Capecitabine	217		
	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505		
		Capecitabine Monotherapy	216		
		Capecitabine/Oxaliplatin (XELOX) Therapy	321		
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473		
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380		
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239		
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524		
		Gemcitabine + Capecitabine Therapy	384		
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day			
		Therapy- 21 day	623		
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691		
		mitoMYcin and Capecitabine Chemoradiation Therapy	727		
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	623		
		Nivolumab and XELOX Therapy	843		
		Capecitabine 830mg/m2 and Radiotherapy – 7 day	523		
		Capecitabine 825mg/m2 and Radiotherapy–7 day	586		
		CARBOplatin	Breast	CARBOplatin (AUC4-6) Monotherapy-21 days	261
				CARBOplatin (AUC4-6) Monotherapy-28 days	251
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348				
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258				
Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430				
DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722				
DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731				
Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775				
DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789				
Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790				
CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734				
Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860				
Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861				
Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857				
	858				

CARBOplatin	Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422	
	Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
	Gynaecology	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419	
		CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308	
		CARBOplatin (AUC4-6) Monotherapy-21 days	261	
		CARBOplatin (AUC4-6) Monotherapy-28 days	251	
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620	
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766	
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811	
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817	
		Head & Neck	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419
			CARBOplatin (AUC4-6) Monotherapy-21 days	261
			CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days	332
			CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle	552
			Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
	CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy		589	
	CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy		591	
	Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy		705	
	Lung		CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271	
		CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304	
		CARBOplatin and Oral Etoposide Therapy-21 days	319	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579	
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568	

CARBOplatin	Lung	PEMEtrexed and CARBOplatin Therapy	318
		Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy	309
		CARBOplatin and vinorelbine Therapy-21 Day	614
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712
		Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713
	Lymphoma and Other	Brentuximab vedotin and ICE Therapy	528
Lymphoma and Other Lymphoproliferative Disorders		ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842
		(R**)-ICE ((ritUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751
Carfilzomib	Plasma Cell Disorders	Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (20/70mg/m2 Once weekly) Dexamethasone (Kd) therapy - 28 day	595
Carfilzomib	Plasma Cell Disorders	Carfilzomib and Dexamethasone (Kd) Therapy - 28 day	566
		Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
Carmustine	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
Carmustine (BCNU)	Transplant	BEAM Autologous Transplant Conditioning Protocol	408
Cemiplimab	Gynaecology	Cemiplimab Therapy	812
	Skin/Melanoma	Cemiplimab Therapy	812
Ceritinib	Lung	Ceritinib Monotherapy	340
Cetuximab	Gastrointestinal	Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		Cetuximab and FOLFOX-4 Therapy	692
		Cetuximab Therapy-14 days	732
		Cetuximab and FOLFOX-6 (modified) Therapy	733
		Cetuximab Monotherapy-7 day	207
	Head & Neck	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
		Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle	417
		Cetuximab Monotherapy-7 day	207
Chlorambucil	Lymphoma and Other Lymphoproliferative Disorders	Chlorambucil10mg/m2 Therapy	411
		Obinutuzumab and Chlorambucil Therapy	286
		ChIVPP (Chlorambucil, vinBLAStine, Procarbazine, prednisoLONE) Therapy	452
CISplatin	Gastrointestinal	CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen	460
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473
		CISplatin and Teysuno-28 day cycle	235

CISplatin	Gastrointestinal	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day	383	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
		Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739	
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816	
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832	
		Genitourinary	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
	CISplatin, Methotrexate and Vinblastine Therapy		337	
	Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day		282	
	Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy		333	
	Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days		338	
	Gemcitabine (1000mg/m2) and CISplatin (35mg/m2) Therapy- 21 day		622	
	Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 21 day		628	
	PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy		602	
	Gynaecology		CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	799	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
		Head & Neck	Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle	417
			CISplatin (100mg/m2) with Radiotherapy (RT)	387
	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)		385	
	CISplatin and 5-Fluorouracil Therapy-28 day		314	
	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy		324	
	DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy		323	
	Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day		517	
	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day		615	
	Pembrolizumab, CISplatin and 5-Fluorouracil Therapy		706	
	DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)		315	
	Lung		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456

CISplatin	Lung	CISplatin (75mg/m2) + Etoposide Therapy-21 day	280
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
		PEMEtrexed and CISplatin Therapy	317
		Vinorelbine and CISplatin Therapy-21 days	339
		Vinorelbine and CISplatin Therapy-28 days	343
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
		DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420
	Neuro-oncology	CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806
	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301
	Plasma Cell Disorders	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496
	Lymphoma and Other		
	Lymphoproliferative Disorders	Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530
	Lymphoma and Other Lymphoproliferative Disorders	(R**)-DHAP Therapy	395
		(R*)- ESHAP Therapy	394
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441
		ESHAP Therapy	838
Cladribine	Lymphoma and Other	Cladribine 0.14mg/kg Day 1 to 5 Therapy	402
		Cladribine 0.14mg/kg Weekly Therapy	469
		Cladribine 5 day and riTUXimab Therapy	531
		Cladribine Weekly and riTUXimab Therapy	534
Cobimetinib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
Crizotinib	Lung	Crizotinib Monotherapy	243
cycloPHOSphamide	Plasma Cell Disorders	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496
cycloPHOSphamide	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250

cycloPHOSphamide	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
	Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857	
		858	
	Gynaecology	EMA/CO Therapy	248
	Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615
	Sarcoma	Etoposide and ifosfamide - vinCRISTine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor	629
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor	630
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
Busulfan/Cyclophosphamide MAC-MUD		639	
Busulfan/Cyclophosphamide MAC-SIB		641	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor		662	

cycloPHOSphamide	Transplant	Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663	
		Fludarabine/ Melphalan with-post transplant cycloPHOSphamide Therapy	868	
	Plasma Cell Disorder	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438	
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299	
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy	273	
		cycloPHOSphamide 1500mg/m2 For Stem Cell Mobilisation	795	
		AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28-Day Therapy	652	
		Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy	779	
		Lymphoma and Other Lymphoproliferative Disorders	CHOEP Therapy– 21 days	396
			Escalated Dose BEACOPP 21 day Therapy	354
	Dose Adjusted R (S/C)-EPOCH Therapy		672	
	(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISTine and PrednisoLONE (*R)-GCVP) Therapy–21 days		737	
	Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) Therapy		801	
	Escalated Dose BEACOPDAC 21 Day Therapy		837	
	Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRISTine. (DA-R-EPOCH) Therapy		355	
	Lymphoma and Other Lymphoproliferative Disorders		(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
			(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293
			(R*)-CHOP – 21 days	307
		(R**) - miniCHOP Therapy – 21 days	436	
		Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241	
		Nordic Therapy	393	
		R-CEOP Therapy – 21 days	510	
		R-CODOX-M Therapy (Patients greater than 65 years)	403	
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466	
		Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days	841	
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days	667	
Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy		833		

cycloPHOSphamide	Lymphoma and Other Lymphoproliferat	Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisoLONE (O-CHOP) Therapy – 21 day	549
		Obinutuzumab cycloPHOSphamide vinCRISTine and prednisoLONE (O-CVP) Therapy – 21 day	550
	CAR-T	Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL	606
		Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL	607
		Fludarabine & cycloPHOSphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)	608
Cyclophosphamide - Oral	Breast	Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
		Dexamethasone, riTUXimab and Cyclophosphamide	532
	Lymphoma and Ot	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410
Cytarabine	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
	Lymphoma and Other Lymphoproliferat ive Disorders	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy	666
		Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530
	Lymphoma and Other Lymphoproliferat ive Disorders	(R**)-DHAP Therapy	395
		Nordic Therapy	393
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		(R*)- ESHAP Therapy	394
		ESHAP Therapy	838
		riTUXimab, dexAMETHasone, Cytarabine and Oxaliplatin((*)-DHAOx) Therapy	834
	Leukaemia and Myeloid Neoplasma	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		FLAG:Ida 8mg/m2 Therapy	362
High Dose Cytarabine Therapy		365	
Intermediate Dose Cytarabine Therapy		364	
FLAG Therapy		363	
Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)		612	
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy		682	
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy		683	

Cytarabine	Leukaemia and	Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy	886
		Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy	887
		Quizartinib, IDArubicin and Cytarabine Induction Therapy	891
	Transplant	BEAM Autologous Transplant Conditioning Protocol	408
		LEAM Autologous Transplant Conditioning Protocol	468
Dabrafenib	Skin/Melanoma	Dabrafenib Monotherapy	237
		Trametinib and Dabrafenib Therapy	415
Dacarbazine	Sarcoma	Dacarbazine (1.2 g/m ²) Therapy – 21 day	511
	Skin/Melanoma	Dacarbazine Therapy	464
	Lymphoma and Other Lymphoproliferative Disorders	ABVD Therapy	290
		Escalated Dose BEACOPDAC 21 Day Therapy	837
Dacomitinib	Lung	Dacomitinib Monotherapy	565
DACTINomycin	Gynaecology	DACTINomycin Therapy	247
		EMA/CO Therapy	248
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
	Sarcoma	Ifosfamide, vinCRISline, DOXOrubicin, DACTINomycin (IVADo) Therapy	754
Darolutamide	Genitourinary	Darolutamide Therapy	693
Daratumumab	Plasma Cell Disorders	Daratumumab (IV), bortezomib and dexamethasone therapy	560
Daratumumab	Plasma Cell Disorders	Daratumumab Monotherapy	426
Daratumumab SC	Plasma Cell Disorders	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	609
		Daratumumab SC Monotherapy	604
		Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy	695
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756
		Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy	779
		Daratumumab SC, lenalidomide and dexamethasone therapy	854
Daunorubicin	Leukaemia and Myeloid Neoplasma	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
		Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy	886
Decitabine	Leukaemia and M	Decitabine Monotherapy – AML (28 day cycle)	231
Degarelix	Genitourinary	Degarelix Therapy- 28 day	481
Denosumab	Supportive Care	Denosumab 120mg Therapy	741

Dinutuximab beta	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548	
DOCEtaxel	Breast	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250	
		DOCEtaxel Monotherapy 100mg/m ² – 21 day cycle	202	
		DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle	203	
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258	
		DOXOrubicin 50mg/m ² /DOCEtaxel 75mg/m ² (AT 50/75) Therapy - 21 day cycle	423	
		Pertuzumab + Trastuzumab + DOCEtaxel	204	
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731	
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789	
		Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle	796	
		Gastrointestinal	DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle	203
			FLOT Therapy-14 day	344
		Genitourinary	DOCEtaxel 75mg/m ² - Prednisolone combination therapy	546
	DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle		203	
	DOCEtaxel 50mg/m ² Monotherapy-14 day		313	
	Gynaecology	DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle	203	
	Head & Neck	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324	
		DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315	
	Lung	DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle	203	
Nindetanib Therapy		372		
Sarcoma	Gemcitabine and DOCEtaxel Therapy - 21 day	501		
Dostarlimab	Gynaecology	Dostarlimab Therapy	819	
DOXOrubicin	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m ² followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485	
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433	
		DOXOrubicin 50mg/m ² /DOCEtaxel 75mg/m ² (AT 50/75) Therapy - 21 day cycle	423	
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252	
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260	

DOXOrubicin	Breast	DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857
			858
	Gastrointestinal	DOXOrubicin (60mg/m2) Therapy	386
	Genitourinary	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day (MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	615
	Sarcoma	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	463
		DOXOrubicin (60) and Ifosfamide Therapy	420
		DOXOrubicin (75) and Ifosfamide Therapy	391
		DOXOrubicin 75mg/m2 Monotherapy	392
		Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	500
			675
			747
		Ifosfamide, vinCRISline, DOXOrubicin, DACTINomycin (IVADo) Therapy	754
	Plasma Cell Disorders	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496
	Lymphoma and Other Lymphoproliferative Disorders	ABVD Therapy	290
		CHOEP Therapy– 21 days	396
		Escalated Dose BEACOPP 21 day Therapy	354
		Dose Adjusted R (S/C)-EPOCH Therapy	672
		Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) Therapy	801
		Escalated Dose BEACOPDAC 21 Day Therapy	837
		Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRISline. (DA-R-EPOCH) Therapy	355

DOXOrubicin	Lymphoma and Other Lymphoproliferative Disorders	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(R*)-CHOP – 21 days	307
		(R**) - miniCHOP Therapy – 21 days	436
		Nordic Therapy	393
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRISine and prednisOLONE (CHOP) Therapy– 21 days	841
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISine and Prednisolone (R-CHOP) Therapy– 21 Days	667
		Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisolONE Therapy	833
		Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISine and prednisolONE (O-CHOP) Therapy – 21 day	549
Durvalumab	Lung	Durvalumab 10mg/kg Monotherapy-14 Day	576
		Durvalumab 1500mg Monotherapy-28 Day	655
Encorafenib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563
Enfortumab vedotin	Genitourinary	Enfortumab vedotin Monotherapy	846
Entrectinib	Lung	Entrectinib Therapy	702
	Tumour Agnostic	Entrectinib Therapy	702
Enzalutamide	Genitourinary	Enzalutamide Monotherapy	233
epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
	Gastrointestinal	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239
Erdafitinib	Genitourinary	Erdafitinib Monotherapy	885
Eribulin	Breast	eriBULin Monotherapy – 28 Day	743
eriBULin	Breast	EriBULLin Monotherapy	228
	Sarcoma	EriBULLin Monotherapy	228
Erlotinib	Lung	Erlotinib Monotherapy	219
Etoposide	Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		EMA/CO Therapy	248
	Gynaecology	PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		Two Day Etoposide CISplatin (EP) Therapy	267
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279

Etoposide	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561	
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271	
		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
		Sarcoma	Ifosfamide Etoposide (IE) Therapy	596
			Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
				747
	Genitourinary/Gyn		Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
			Etoposide and CISplatin 20mg/m2 (EP) Therapy	301
	Transplant		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
	Lymphoma and Other Lymphoproliferative Disorders		CHOEP Therapy– 21 days	396
			Escalated Dose BEACOPP 21 day Therapy	354
			SMILE Therapy (NK or T-cell lymphoma)	407
			Brentuximab vedotin and ICE Therapy	528
			Dose Adjusted R (S/C)-EPOCH Therapy	672
			ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842
			Escalated Dose BEACOPDAC 21 Day Therapy	837
			Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530
			Dose Adjusted riTUXImab, Etoposide, prednisolONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. (DA-R-EPOCH) Therapy	355
			Lymphoma and Other Lymphoproliferative Disorders	
	R-CEOP Therapy – 21 days	510		
	R-IVAC Therapy (Patients greater than 65 years)	404		
	R-IVAC Therapy (Patients less than or equal to 65 years)	399		
	(R*)- ESHAP Therapy	394		
	(R*)-ICE ((riTUXImab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751		
	ESHAP Therapy	838		
	Transplant	BEAM Autologous Transplant Conditioning Protocol		
	LEAM Autologous Transplant Conditioning Protocol	468		
etoposide	Plasma Cell Disorders	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496	
Etoposide Oral	Lung	CARBOplatin and Oral Etoposide Therapy-21 days	319	
		Oral Etoposide Therapy	388	
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689	

Etoposide Oral	Lymphoma and Other Lymphoproliferative Disorders	R-CEOP Therapy – 21 days	510	
	Everolimus	Breast	Everolimus and Exemestane Therapy	322
Genitourinary		Everolimus Monotherapy	320	
Neuroendocrine		Everolimus Monotherapy	320	
Exemestane	Breast	Everolimus and Exemestane Therapy	322	
		Exemestane Monotherapy	376	
Fedratinib	Leukaemia and Myeloid Neoplasma	Fedratinib Therapy	788	
Fludarabine	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611	
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635	
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636	
		Fludarabine/ Melphalan with-post transplant cycloPHOSphamide Therapy	868	
		Lymphoma and Other Lymphoproliferative Disorders	Fludarabine, Cyclophosphamide and ritUXimab (FC IV+R) Therapy	241
	Fludarabine, Cyclophosphamide and ritUXimab (FC Oral+R) Therapy		410	
	Leukaemia and Myeloid Neoplasma		FLAG:Ida 8mg/m2 Therapy	362
		FLAG Therapy	363	
		CAR-T	Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL	606
	Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL		607	
	Fludarabine & cycloPHOSphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)		608	
	Folinic Acid	Gastrointestinal	Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
			FLOT Therapy-14 day	344
			FLOX Therapy	486
FOLFIRI (14 days)+ Cetuximab (14 days) Therapy			585	
FOLFIRI (14 days)+ Cetuximab (7 days) Therapy			328	
FOLFIRI Therapy-14 day			227	
FOLFIRINOX Therapy			329	
FOLFOX-4 Therapy-14 day			210	
FOLFOXIRI Therapy			555	
Modified FOLFIRINOX Therapy			515	
Modified FOLFOX-6 Chemoradiation Therapy-14 day			509	
Modified FOLFOX-6 Therapy-14 day			209	
Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen			427	
Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day			448	
Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day			447	
QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly			428	

Folinic Acid	Gastrointestinal	Roswell Park Modified (Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen	427
		5-Fluorouracil and Folinic Acid Therapy-14 day	660
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Cetuximab and FOLFOX-4 Therapy	692
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
		Cetuximab and FOLFOX-6 (modified) Therapy	733
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
		Pembrolizumab and FOLFOX-6 Modified Therapy	839
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
		Lymphoma and Other Lymphoproliferative Disorders	SMILE Therapy (NK or T-cell lymphoma)
riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664		
Lymphoma and Other Lymphoproliferative Disorders	R-CODOX-M Therapy (Patients greater than 65 years)	403	
	R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
Fruquintinib	Gastrointestinal	Fruquintinib Monotherapy	890
Fulvestrant	Breast	Fulvestrant Therapy	361
Gefitinib	Lung	Gefitinib Monotherapy	220
Gemcitabine	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430
		Gemcitabine (1000mg/m ²) and Capecitabine (830mg/m ²) Therapy - 28 days	524
	Gastrointestinal	Gemcitabine (1000mg/m ²) and CISplatin (25mg/m ²) Therapy- 21 day	383
		Gemcitabine (1000mg/m ²) and RT therapy	521
		Gemcitabine (1000mg/m ²) Monotherapy - 28 day	284
		Gemcitabine (1000mg/m ²) Monotherapy - 56 day	283
		Gemcitabine (400mg/m ²) and RT therapy	522
		Gemcitabine (600mg/m ²) and RT therapy	559
		Gemcitabine + Capecitabine Therapy	384
		Nab-PACLitaxel and Gemcitabine – 28 day	256
	Genitourinary	Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) Therapy- 28 day	282
		Gemcitabine (1000mg/m ²) and CISplatin (35mg/m ²) Therapy- 21 day	622
		Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) Therapy- 21 day	628
		Gemcitabine (100mg/m ²) and Radiotherapy	759
	Gynaecology	Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 4) Therapy- 21 day	306
		Gemcitabine (1000mg/m ²), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499
	Head & Neck	Gemcitabine (1250mg/m ²) and CISplatin (80mg/m ²) Therapy - 21 day	517
		Gemcitabine (1250mg/m ²) Monotherapy - 21 day	514

Gemcitabine	Lung	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Gemcitabine (1000mg/m2) Monotherapy - 28 day	284
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501
	Breast	Gemcitabine (800mg/m2) Monotherapy - 28 Day	749
	Lymphoma and Other Lymphoproliferative Disorders	(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISStine and PrednisolONE (*R)-GCVP) Therapy–21 days	737
	Lymphoma and Other Lymphoproliferative Disorders	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**) -GDP)	506 441
Gemtuzumab ozogamicin	Leukaemia and Myeloid Neoplasma	Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
Goserelin	Genitourinary	Goserelin 10.8mg-12 Weekly Therapy	477
		Goserelin 3.6mg Therapy- 4 weeks	478
Ibrutinib	Lymphoma and Other Lymphoproliferative Disorders	Ibrutinib Therapy (Mantly Cell Lymphoma)	297
	Lymphoma and Other Lymphoproliferative Disorders	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)	296
Idarubicin	Leukaemia and Myeloid Neoplasma	FLAG:Ida 8mg/m2 Therapy	362
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
		Quizartinib, IDArubicin and Cytarabine Induction Therapy	891
Idelalisib	Lymphoma and Other Lymphoproliferative Disorders	Idelalisib and riTUXimab Therapy	389
		Idelalisib Monotherapy	291
Ifosfamide	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy	602
	Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
		Ifosfamide Etoposide (IE) Therapy	596
		Etoposide and ifosfamide - vinCRISStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
		High Dose Ifosfamide Therapy- 21 day	680
Ifosfamide, vinCRISStine, DOXOrubicin, DACTINomycin (IVADo) Therapy	754		

Ifosfamide	Lymphoma and Other Lymphoproliferative Disorders	SMILE Therapy (NK or T-cell lymphoma)	407	
		Brentuximab vedotin and ICE Therapy	528	
		ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842	
	Lymphoma and Other Lymphoproliferative Disorders	(R**) -ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	
		R-IVAC Therapy (Patients greater than 65 years)	404	
		R-IVAC Therapy (Patients less than or equal to 65 years)	399	
		(R*) -ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751	
	Imatinib	Sarcoma	Imatinib Therapy-GIST	335
	Inotuzumab ozogamicin	Leukaemia and Myeloid Neoplasma	Inotuzumab ozogamicin Monotherapy	537
	Ipilimumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
Genitourinary			Nivolumab 3mg Ipilimumab 1mg Therapy	551
Lung			Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712	
		Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713	
Skin/Melanoma		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714	
		Ipilimumab Monotherapy	105	
Irinotecan		Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy		431	
	Aflibercept-14 days		238	
	Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days		449	
	Cetuximab (14 days) and Irinotecan (14 days) Therapy		331	
	Cetuximab (7 days) and Irinotecan (14 days) Therapy		330	
	FOLFIRI (14 days)+ Cetuximab (14 days) Therapy		585	
	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy		328	
	FOLFIRI Therapy-14 day		227	
	FOLFIRINOX Therapy		329	
	FOLFOXIRI Therapy		555	
	Irinotecan Monotherapy - 21 days		213	
	Modified FOLFIRINOX Therapy		515	
	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day		448	
	Irinotecan 150mg/m2 Monotherapy - 28 days	654		
FOLFIRINOX Therapy - (Rectal Carcinoma)	691			
Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783			
Sarcoma	Irinotecan and Temozolomide Therapy- 21 days	504		
	vinCRISTine, Irinotecan and Temozolomide (VIT) Therapy	757		
Isotretinoin	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548	
Ixazomib	Plasma Cell Disorders	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516	
Lapatinib	Breast	Lapatinib and Capecitabine	217	
Larotrectinib	Tumour Agnostic	Larotrectinib Monotherapy - Adult	758	
		Larotrectinib Monotherapy - Paediatric	P00760	

L-Asparaginase	Lymphoma and Other Lymphoproliferative Disorders	SMILE Therapy (NK or T-cell lymphoma)	407
Lenalidomide	Plasma Cell Disorders	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
		Lenalidomide 25mg and Dexamethasone Therapy - 28 day	218
		Carfilzomib (56mg/m ² once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (27mg/m ² twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643
		Bortezomib, Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781
		Lenalidomide RVD lite Maintenance Therapy	782
		Daratumumab SC, lenalidomide and dexamethasone therapy	854
Lenvatinib	Gastrointestinal	Lenvatinib -HCC Therapy	644
Lenvatinib	Head & Neck	Lenvatinib (Lenvima) -DTC Therapy	295
Letrozole	Breast	Letrozole Monotherapy	371
Leuprorelin	Genitourinary	Leuprorelin 3.75mg Therapy-28 day	494
		Leuprorelin 30mg Therapy- 24 weeks	493
		Leuprorelin 45mg Therapy- 24 week	491
		Leuprorelin 7.5mg Therapy- 28 day	490
		Leuprorelin 11.25mg Therapy- 12 weeks	492
Leuprorelin	Genitourinary	Leuprorelin 22.5mg Therapy- 12 weeks	479
Lomustine	Neuro-oncology	Procarbazine Lomustine and VinCRiStine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRiStine (PCV) Therapy – 56 days	658
		Lomustine and Bevacizumab 5mg/kg Therapy	742
		Lomustine and Bevacizumab 7.5mg/kg Therapy	804
		Lomustine 130mg/m ² Therapy	805
		CiSPlatin, Lomustine and vinCRiStine (CLV) Therapy	806
	Transplant	LEAM Autologous Transplant Conditioning Protocol	468
Lorlatinib	Lung	Lorlatinib therapy	570
Lutetium oxodotreotide	Gastrointestinal, n	Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy	642
Melphalan	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
		Fludarabine/ Melphalan with-post transplant cycloPHOSphamide Therapy	868
		Bortezomib , Melphalan and Prednisolone	275
	Plasma Cell Disorders/ Transplant	High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
	Transplant	BEAM Autologous Transplant Conditioning Protocol	408
	LEAM Autologous Transplant Conditioning Protocol	468	
MESNA	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Plasma Cell Disorders	Cyclophosphamide 2000mg/m ² For Stem Cell Mobilisation	438

MESNA	Lymphoma and Other Lymphoproliferative Disorders	SMILE Therapy (NK or T-cell lymphoma)	407
	Methotrexate	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy
Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy			378
Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy			377
Genitourinary		CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338
Gynaecology		EMA/CO Therapy	248
		Intrathecal Methotrexate for CNS Prophylaxis in GTN	249
		Methotrexate 8 day Charing Cross Regimen	246
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
Sarcoma		(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
		VinBLASStine and Methotrexate Therapy	554
Transplant		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor	629
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor	630
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor	662
	Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663	
Lymphoma and Other Lymphoproliferative Disorders	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508	
	SMILE Therapy (NK or T-cell lymphoma)	407	
	riTUXimab, Methotrexate, Procarbazine and vinCRISStine (R-MPV) – 14 Days Induction Therapyi	664	
	High Dose Methotrexate (3000mg/m2) Therapy 3 hour infusion (CNS prophylaxis)	439	
	High Dose Methotrexate (3000mg/m2) Therapy – 24 hour infusion (CNS prophylaxis)	665	
Lymphoma and Other Lymphoproliferative Disorders	R-CODOX-M Therapy (Patients greater than 65 years)	403	
	R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	

Methotrexate	Lymphoma and	riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
Methylprednisolone	Lymphoma and Other	(R*)- ESHAP Therapy	394
		ESHAP Therapy	838
Midostaurin	Leukaemia and Myeloid Neoplasma	Midostaurin Maintenance Therapy	661
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
		Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy	683
Mifamurtide	Sarcoma	Mifamurtide	100
mitoMYcin	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
		mitoMYcin and Capecitabine Chemoradiation Therapy	727
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
Mogamulizumab	Lymphoma and Other Lymphoproliferative Disorders	Mogamulizumab Therapy	761
Momelotinib	Leukaemia and Myeloid Neoplasma	Momelotinib Therapy	867
nab-PACLitaxel	Breast	Atezolizumab and nab-PACLitaxel Therapy	688
		nab-PACLitaxel Weekly Monotherapy–28 day	736
	Gastrointestinal	Nab-PACLitaxel and Gemcitabine – 28 day	256
Nab-PACLitaxel (Abraxane®)	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	230
Neratinib	Breast	Neratinib Therapy	720
Nindetanib	Lung	Nindetanib Therapy	372
Niraparib Tablets	Gynaecology	Niraparib Tablets Monotherapy	862
Niraparib/abiraterone	Genitourinary	Niraparib and Abiraterone acetate (Akeega®) and prednisolONE Therapy	848
Nivolumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832
		Nivolumab and FOLFOX-6 Modified Therapy	844
		Nivolumab and XELOX Therapy	843
	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Head & Neck	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Lung	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
Nivolumab 360mg and Ipilimumab 1mg/kg Therapy		792	
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy		712	
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy		713	
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714

Nivolumab	Lung	Nivolumab 360mg and Chemotherapy	849	
	Skin/Melanoma	Nivolumab 3mg Ipilimumab 1mg Therapy	551	
		Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431	
		Lymphoma and Other Lymphoproliferative Disorders	Nivolumab Monotherapy 240mg-14 day	483
Lymphoma and Other Lymphoproliferative Disorders	Nivolumab Monotherapy 480mg-28day	484		
Obinutuzumab	Lymphoma and Other	Obinutuzumab and Bendamustine Therapy-28 day cycle	424	
		Obinutuzumab and Chlorambucil Therapy	286	
		Obinutuzumab Maintenance Therapy -56 day	425	
		Venetoclax and obinutuzumab Therapy	715	
		Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisoLONE (O-CHOP) Therapy – 21 day	549	
		Obinutuzumab cycloPHOSphamide vinCRISTine and prednisoLONE (O-CVP) Therapy – 21 day	550	
Olaparib	Breast	Olaparib (Tablet) Monotherapy	588	
	Genitourinary	Olaparib (Tablet) Monotherapy	588	
	Gynaecology	Olaparib (Tablet) Monotherapy	588	
		Olaparib (Tablet) and Bevacizumab Therapy	746	
	Gastrointestinal	Olaparib (Tablet) Monotherapy	588	
Osimertinib	Lung	Osimertinib Monotherapy	353	
Oxaliplatin	Gastrointestinal	Capecitabine/Oxaliplatin (XELOX) Therapy	321	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		Cetuximab and FOLFOX-4 Therapy	692	
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Pembrolizumab and FOLFOX-6 Modified Therapy	839	
		Nivolumab and FOLFOX-6 Modified Therapy	844	
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Nivolumab and XELOX Therapy	843	
		Lymphoma and Other	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506
			riTUXimab, dexAMETHasone, Cytarabine and Oxaliplatin((*R)-DHAOx) Therapy	834

PACLitaxel	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790
		Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle	797
		PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
	Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857	
		858	
	Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226

PACLitaxel	Genitourinary	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		PACLitaxel, Ifosfamide, and CISPlatin (TIP) Therapy	602
	Gynaecology	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303
		PACLitaxel/CISPlatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		CISPlatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy	769
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISPlatin 50mg/m2 Therapy	799
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817
		Lung	CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy
	Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy		579
	Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy		309
	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day		226
	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712		
Palbociclib	Breast	Palbociclib Therapy-28 day	414
Panitumumab	Gastrointestinal	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		Panitumumab 6mg/kg Therapy	225
Pazopanib	Genitourinary	Pazopanib Therapy	445
	Sarcoma	Pazopanib Therapy	445
Pegylated Liposoma	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy	772
	Sarcoma	Pegylated Liposomal DOXOrubicin 20mg/m2 21 days	462
Pegylated Liposoma	Breast	Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
	Gynaecology	Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624
		Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
	Sarcoma	Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
Pembrolizumab	Breast	Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860

Pembrolizumab	Breast	Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857
			858
	Gastrointestinal	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739
		Pembrolizumab and FOLFOX-6 Modified Therapy	839
	Genitourinary	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg and Axitinib Therapy	583
	Gynaecology	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817
	Head & Neck	Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706
	Lung	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
	Skin/Melanoma	Pembrolizumab 200mg Monotherapy	455
Pembrolizumab 400mg Monotherapy		558	
Paediatric Oncology	Pembrolizumab Paediatric Monotherapy	P00711	
Head and Neck	Pembrolizumab 200mg Monotherapy	455	
Lymphoma and Other Lymphoproliferative Disorders	Pembrolizumab 200mg Monotherapy	455	
Lymphoma and Other Lymphoproliferative Disorders	Pembrolizumab 400mg Monotherapy	558	
PEMEtrexed	Lung	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
		PEMEtrexed and CARBOplatin Therapy	318
		PEMEtrexed and CISplatin Therapy	317
		PEMEtrexed Monotherapy	222
		Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714
Pemigatinib	Gastrointestinal	Pemigatinib Therapy	889
Pertuzumab	Breast	Pertuzumab + Trastuzumab + DOCetaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and Vinorelbine	526

Pertuzumab	Breast	Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		Pertuzumab and Trastuzumab Therapy	726
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775
Pertuzumab/Trastuzumab	Breast	Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy	785
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790
		Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle	796
		Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle	797
		Pertuzumab Trastuzumab (Phesgo®) and vinorelbine	798
Pixantrone	Lymphoma and Other Lymphoproliferative Disorders	Pixantrone Therapy	255
Plerixafor	Plasma Cell Disorders	Plerixafor and G-CSF Therapy	536
Polatuzumab vedotin	Lymphoma and Other Lymphoproliferative Disorders	Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685
	Lymphoma and Other Lymphoproliferative Disorders	Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy	833
Pomalidomide	Plasma Cell Disorders	Pomalidomide and Dexamethasone	245
Pomalidomide	Plasma Cell Disorders	Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601
Ponatinib	Leukaemia and Myeloid Neoplasma	Ponatinib Therapy	302
prednisoLONE	Genitourinary	Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy	848
Procarbazine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658
	Lymphoma and Other Lymphoproliferative Disorders	Escalated Dose BEACOPP 21 day Therapy	354
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapy	664

Procarbazine	Lymphoma and Other	ChIVPP (Chlorambucil, vinBLASTine, Procarbazine, prednisoLONE) Therapy	452					
	Lymphoproliferat							
Quizartinib	Leukaemia and M	Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy	886					
		Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy	887					
		Quizartinib, IDArubicin and Cytarabine Induction Therapy	891					
Radium 223	Genitourinary	Radium 223 Therapy	257					
Regorafenib	Gastrointestinal	Regorafenib Monotherapy	244					
Relugolix	Genitourinary	Relugolix Therapy	830					
Ribociclib	Breast	Ribociclib Therapy-28 day	525					
		Ribociclib Therapy (Adjuvant) - 28 day	892					
riTUXimab	Lymphoma and Other	Lymphoproliferat	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508				
				riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664			
				Dose Adjusted R (S/C)-EPOCH Therapy	672			
				Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685			
				(*riTUXimab)-Gemcitabine Cyclophosphamide				
				vinCRISTine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737			
	Lymphoma and Other	Lymphoproliferat	Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRISTine. (DA-R-EPOCH) Therapy	355				
				Lymphoma and Other	Lymphoproliferat	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409	
							(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293
							(R*)-CHOP – 21 days	307
							(R**)- miniCHOP Therapy – 21 days	436
							(R**)-DHAP Therapy	395
							(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
Cladribine 5 day and riTUXimab Therapy	531							
Cladribine Weekly and riTUXimab Therapy	534							
Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532							
Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241							
Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410							
Idelalisib and riTUXimab Therapy	389							
Nordic Therapy	393							
R-CEOP Therapy – 21 days	510							
R-CODOX-M Therapy (Patients greater than 65 years)	403							
R-CODOX-M Therapy (Patients less than or equal to 65 years)	398							
R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506							

riTUXimab	Lymphoma and	riTUXimab 375 mg/m2 Combination Therapy-21 day	542
		RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day	543
		RiTUXimab 375 mg/m2 Maintenance Therapy-84 day	540
		RiTUXimab 375 mg/m2 Therapy-7 day	541
		riTUXimab and Bendamustine Therapy	345
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		Venetoclax and Rituximab therapy	575
		(R*)- ESHAP Therapy	394
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441
		RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day	599
		RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day	600
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRiStine and Prednisolone (R-CHOP) Therapy– 21 Days	667
		(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751
		Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisolONE Therapy	833
riTUXimab, dexAMETHasone, Cytarabine and Oxaliplatin((R*)-DHAOx) Therapy	834		
Ruxolitinib	Leukaemia and Myeloid Neoplasma	Ruxolitinib Monotherapy	229
Sacituzumab Govitec	Breast	Sacituzumab Govitecan Therapy	794
Siltuximab	Lymphoma and Other Lymphoproliferative Disorders	Siltuximab Monotherapy	277
Sorafenib	Gastrointestinal	Sorafenib Therapy	294
	Genitourinary	Sorafenib Therapy	294
	Head & Neck	Sorafenib Therapy	294
Sunitinib	Genitourinary	SUNitinib 50mg Therapy (21 days)	719
	Sarcoma	SUNitinib 50mg Therapy (21 days)	719
Sunitinib	Genitourinary	Sunitinib 50mg Therapy	325
	Sarcoma	Sunitnib 50mg Therapy	325
	Neuroendocrine	Sunitnib 37.5mg Therapy	327
Talazoparib	Breast	Talazoparib Therapy	605
Tamoxifen	Breast	Tamoxifen Monotherapy	253
Teclistamab	Plasma Cell Disorders	Teclistamab Monotherapy	865
Temozolomide	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505
	Sarcoma	Irinotecan and Temozolomide Therapy- 21 daysi	504
	Neuro-oncology	Temozolomide Recurrent Therapy	342
		Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years	461
		Temozolomide with RT and Adjuvant Therapy	334
temozolomide	Sarcoma	vinCRiStine, Irinotecan and Temozolomide (VIT) Therapyi	757
Temsirolimus	Genitourinary	Temsirolimus Monotherapy	326
Tepotinib	Lung	Tepotinib Therapy	823

Teysuno	Gastrointestinal	CISplatin and Teysuno-28 day cycle	235
Thalidomide	Plasma Cell Disorder	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756
Thalidomide	Plasma Cell Disorder	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496
Thiotepa	Lymphoma and Other Lymphoproliferative Disorders	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
Tisagenlecleucel	CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL	686
		Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL	687
Tivozanib	Genitourinary	Tivozanib Therapy	564
Topotecan	Gynaecology	Topotecan Monotherapy-5 day	311
		Topotecan Monotherapy-Weekly	312
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771
	Lung	Topotecan Monotherapy-5 day	311
		Topotecan Oral Monotherapy	587
Trabectedin	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
	Sarcoma	Trabectedin Monotherapy	374
Trametinib	Skin/Melanoma	Trametinib and Dabrafenib Therapy	415
Trastuzumab	Breast	Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775
	Gastrointestinal	Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
Trastuzumab	Breast	PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
Trastuzumab deruxi	Breast	Trastuzumab Deruxtecan (Enhertu®) Therapy	776
Trastuzumab emtar	Breast	Trastuzumab Emtansine (Kadcyla®) Early Breast Cancer Therapy- 21 days	659
Trastuzumab Emtansine (Kadcyla®)	Breast	Trastuzumab Emtansine (Kadcyla®) - 21 days	206
Trastuzumab IV	Breast	Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and Vinorelbine	526

Trastuzumab IV	Breast	Pertuzumab Trastuzumab and Weekly PAClitaxel Therapy - 21 day cycle	507
		Trastuzumab (IV) Monotherapy 21 days	200
		Trastuzumab (IV) Monotherapy 7 days	201
		Pertuzumab and Trastuzumab Therapy	726
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PAClitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
Trastuzumab SC	Gastrointestinal	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502
	Breast	Trastuzumab SC 21 days-Early Breast Cancer	285
Trastuzumab	Breast	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	272
		PAClitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
		DOCetaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
Trastuzumab IV	Breast	DOCetaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722
		DOCetaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731
Tretinoin (ATRA)	Leukaemia and Myeloid Neoplasma	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Trifluridine and Tipiracil	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Triptorelin	Genitourinary	Triptorelin 11.25mg Therapy- 12 weeks	480
		Triptorelin 22.6mg Therapy- 24 weeks	488
		Triptorelin 3mg Therapy- 28 day	489
Vandetanib	Head & Neck	Vandetanib Monotherapy	242
Vemurafenib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
		Vemurafenib Monotherapy	102
Venetoclax	Lymphoma and Other Lymphoproliferative Disorders	Venetoclax Monotherapy	400
Venetoclax	Lymphoma and Other Lymphoproliferative Disorders	Venetoclax and obinutuzumab Therapy	715
		Venetoclax and azaCITIDine Therapy	852
Venetoclax	Lymphoma and Other Lymphoproliferative Disorders	Venetoclax and Rituximab therapy	575
Vinblastine	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338
	Sarcoma	VinBLAStine and Methotrexate Therapy	554
	Lymphoma and Other Lymphoproliferative Disorders	ABVD Therapy	290

Vinblastine	Lymphoma and Other		
	Lymphoproliferative Disorders	ChIVPP (Chlorambucil, vinBLASTine, Procarbazine, prednisolONE) Therapy	452
VinCRISTine	Gynaecology	EMA/CO Therapy	248
	Sarcoma	Etoposide and ifosfamide - vinCRISTine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
Ifosfamide, vinCRISTine, DOXOrubicin, DACTINomycin (IVADo) Therapy		754	
vinCRISTine, Irinotecan and Temozolomide (VIT) Therapyi		757	
Procarbazine Lomustine and VinCRISTine (PCV) Therapy		379	
Neuro-oncology	Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658	
	CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806	
Lymphoma and Other Lymphoproliferative Disorders	CHOEP Therapy– 21 days	396	
	Escalated Dose BEACOPP 21 day Therapy	354	
	riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664	
	Dose Adjusted R (S/C)-EPOCH Therapy	672	
	(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISTine and PrednisolONE (*R)-GCVP) Therapy–21 days	737	
	Escalated Dose BEACOPDAC 21 Day Therapy	837	
	Dose Adjusted riTUXimab, Etoposide, prednisolONE, DOXOrubicin, cycloPHOSphamide and vinCRISTine. (DA-R-EPOCH) Therapy	355	
	Lymphoma and Other Lymphoproliferative Disorders	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293
(R*)-CHOP – 21 days		307	
(R**) - miniCHOP Therapy – 21 days		436	
Nordic Therapy		393	
R-CEOP Therapy – 21 days		510	
R-CODOX-M Therapy (Patients greater than 65 years)		403	
R-CODOX-M Therapy (Patients less than or equal to 65 years)		398	
riTUXimab-HyperCVAD Therapy (MCL) – Part A		466	
Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisolONE (CHOP) Therapy– 21 days		841	
riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days		667	
Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisolONE (O-CHOP) Therapy – 21 day		549	
Obinutuzumab cycloPHOSphamide vinCRISTine and prednisolONE (O-CVP) Therapy – 21 day		550	

Vinorelbine IV	Breast	Intravenous Vinorelbine Monotherapy-21day	232
		Pertuzumab Trastuzumab and Vinorelbine	526
		Pertuzumab Trastuzumab (Phesgo®) and vinorelbine	798
	Gynaecology	Intravenous Vinorelbine Monotherapy-21day	232
	Lung	Intravenous Vinorelbine Monotherapy-21day	232
		Vinorelbine and CISplatin Therapy-21 days	339
		Vinorelbine and CISplatin Therapy-28 days	343
CARBOplatin and vinorelbine Therapy-21 Day		614	
Vinorelbine Oral	Breast	Oral Vinorelbine Monotherapy-7days	259
	Lung	Oral Vinorelbine Monotherapy-7days	259
Vinorelbine Oral	Breast	Pertuzumab Trastuzumab and Vinorelbine	526
		Pertuzumab Trastuzumab (Phesgo®) and vinorelbine	798
	Lung	CARBOplatin and vinorelbine Therapy-21 Day	614
Vismodegib	Skin/Melanoma	Vismodegib Monotherapy	236
Vyxeos liposomal® (Leukaemia and Myeloid Neoplasma	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction Therapy	613
		Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation Therapy	618
Zanubrutinib	Lymphoma and Other Lymphoproliferative Disorders	Zanubrutinib Therapy	708
Zoledronic acid	Breast	Zoledronic acid monotherapy	545
	Supportive Care	Zoledronic Acid Therapy-28 days	723
		Zoledronic Acid Therapy-3 monthly	724
		Zoledronic Acid Therapy-6 monthly	725